“Comparable Efficacy of Mobocertinib and Amivantamab in Advanced NSCLC with EGFR Exon 20 Insertions Previously Treated with Platinum-Based Chemotherapy: A Study”

https://pubmed.ncbi.nlm.nih.gov/38114357

The study found that in patients with advanced non-small cell lung cancer with EGFR exon 20 insertions previously treated with platinum-based chemotherapy, mobocertinib and amivantamab have similar efficacy.